| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cytosorbents Corporation$0.38
+0.01 (+2.5%)
F 13Pipeline Score MedTech · Clinical
Market Cap
28.94 M
EPS
-0.19
P/E Ratio
-
Value Trade
607.70 K
SEC Financials
Q1 2026Dilution Risk
35%Revenue
8.86 M
R&D Expenses
1.02 M
Operating CF
-1.16 M
Total Assets
40.56 M
Total Liabilities
38.37 M
Equity
2.19 M
D/E Ratio
12,345
-12.53 %
Week
-24.52 %
1 Month
-29.65 %
3 Month
-25.94 %
6 Month
-94.59 %
5 Year
-91.99 %
All Time
Cash Data
Cash Position
6.33 M
Monthly Burn
387.00 K
Runway
14.7 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
42.38 K
52 Week Range
0.44 - 1.39
% held by Insiders
17.6 %
% held by Institutions
26.21 %
Enterprise Value
53.67 M
Total Shares
62.81 M
Short %
3.9 %
Float Shares
53.33 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F13
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 10%
Micro Cap (rank 821 of 911)
Percentile RankCytosorbents Corporation has significant pipeline risk (13/100).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CytoSorb hemoperfusion Unknown | Sepsis | Phase 3 | NCT04643639 | 65% | - | COMPLETED | 24 | - | - | Oct 19, 2022 | - | Dec 22, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DrugSorb-ATR | cardiac surgery | — | 2025-09-29 | first randomized controlled trial data demonstrating that intraoperative use of DrugSorb™-ATR significantly reduces levels of direct oral anticoagulants (DOACs); significant reductions in severe bleeding complications compared with patients treated with aspirin + Plavix (clopidogrel) without CytoSorb Read More | CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen Read More | |
DrugSorb-ATR | cardiac surgery | — | 2025-09-29 | first randomized controlled trial data demonstrating that intraoperative use of DrugSorb™-ATR significantly reduces levels of direct oral anticoagulants (DOACs); significant reductions in severe bleeding complications compared with patients treated with aspirin + Plavix (clopidogrel) without CytoSorb Read More | CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen Read More | |
DrugSorb-ATR | cardiac surgery | — | 2025-09-29 | first randomized controlled trial data demonstrating that intraoperative use of DrugSorb™-ATR significantly reduces levels of direct oral anticoagulants (DOACs); significant reductions in severe bleeding complications compared with patients treated with aspirin + Plavix (clopidogrel) without CytoSorb Read More | CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CTSO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CTSO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CTSO▼ -8.1%on this news
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026
CytoSorbents Corporation (NASDAQ: CTSO) announced that Dr. Phillip Chan, CEO, will present at the Life Sciences Forum on June 24, 2026. Following the presentation, the company will host a Q&A session and has scheduled one-on-one meetings with investors on June 30, 2026. CytoSorbents focuses on blood purification treatment technologies for critical illnesses, and their flagship product, CytoSorb, is approved in the EU and used worldwide. However, the company is still pursuing necessary regulatory approvals in the U.S. and Canada.
Read more →CTSOCytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
CytoSorbents Corporation reported its financial results for Q1 2026, showing a 2% increase in revenue to $8.9 million. The company experienced a net loss of $5.1 million, attributed largely to foreign currency fluctuations. Despite challenges, including geopolitical issues affecting sales in the Middle East, the company is focused on improving operational efficiency and pursuing FDA submissions for its DrugSorb-ATR device.
Read more →CTSOCytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
CytoSorbents Corporation will report its first quarter 2026 financial results on May 13, 2026. The company is known for its blood purification technologies used in critical care and cardiac surgery. A live conference call will follow the report, allowing for a Q&A session. CytoSorbents has received FDA Emergency Use Authorization for its products in COVID-19 treatment.
Read more →CTSO▼ -10.6%on this news
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation reported a 4% increase in sales for 2025, reaching $37.1 million, despite a 10% decline in Germany. The company achieved over 300,000 cumulative CytoSorb treatments globally and is making progress with the FDA on DrugSorb-ATR. The CEO highlighted a focus on improving clinical outcomes and achieving cash flow breakeven in 2026.
Read more →CTSOCytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
CytoSorbents Corporation has announced significant advancements at ISICEM 2026, including the launch of HotSwap™, a new system for rapid blood purification device exchanges. The company also renewed its partnership with Aferetica, enhancing its distribution in Italy. Additionally, new clinical evidence presented reinforces the efficacy of CytoSorb therapy in treating critical conditions.
Read more →CTSOCytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation will report its fourth quarter and full year financial results for 2025 on March 25, 2026. The company specializes in blood purification technologies used in critical care. A live presentation will follow the report, with an archived recording available later. CytoSorbents is also pursuing FDA approval for its DrugSorb-ATR system.
Read more →CTSOCytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
CytoSorbents Corporation reported preliminary unaudited financial results for the fourth quarter and full-year 2025, expecting approximately $9.2 million in Q4 revenue and $37.0 million in total revenue for the year. The company is set to engage with the FDA for a De Novo Application regarding DrugSorb®-ATR, with regulatory approval anticipated in mid-2026. Notably, the results of the pivotal STAR-T study have been accepted for publication, highlighting the clinical significance of their technology within cardiac surgery. Additionally, CytoSorbents has reached a milestone of over 300,000 treatments delivered globally.
Read more →CTSO▼ -12.3%on this news
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
CytoSorbents Corporation announced that CEO Dr. Phillip Chan and CFO Peter J. Mariani will participate in a virtual fireside chat with D. Boral Capital on December 15, 2025. The discussion will focus on the company's recent financial performance, regulatory advancements for DrugSorb-ATR, and future growth prospects. This event follows a strong earnings report highlighting significant sales and a robust balance sheet.
Read more →CTSO▼ -5.3%on this news
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
CytoSorbents Corporation will present at the Jefferies Global Healthcare Conference from November 17-20, 2025, in London. The presentation is scheduled for November 18 at 12:30 PM GMT. This announcement updates previous communications regarding the event and highlights the company's innovative blood purification technologies used in critical care settings.
Read more →CTSOCytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
CytoSorbents Corporation reported strong financial results for Q3 2025, with record sales and improved margins, despite a decline in the German market. The company is implementing a workforce reduction plan to achieve cash flow breakeven by Q1 2026. Additionally, they amended their credit agreement to strengthen their balance sheet and support their regulatory submission for DrugSorb-ATR.
Read more →CTSOCytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
CytoSorbents Corporation, a leader in blood purification technology for life-threatening conditions, will participate in the Jefferies Global Healthcare Conference in London on November 18-19, 2025. CEO Dr. Phillip Chan and CFO Mr. Peter Mariani will hold one-on-one meetings with investors at this notable event. The conference is significant for fostering discussions among executives, investors, and strategists across the healthcare industry, covering various sectors including biotech and medical technology. CytoSorbents' proprietary technologies offer critical applications in intensive care, especially during cardiothoracic surgery.
Read more →CTSOCytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation is set to report its third quarter 2025 financial results and recent business highlights on November 13, 2025. The company, known for its blood purification technologies, is actively pursuing regulatory approvals for its products while emphasizing its commitment to treating life-threatening conditions. Health care professionals and stakeholders can participate in a live conference call and webcast to gain insights into the company's operational developments and future outlook.
Read more →CTSOIn Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
CytoSorbents Corporation commemorates Dr. Robert Hawes Bartlett, who served as Chief Medical Officer from 2008 to 2017 and was instrumental in the development of ECMO technology. He passed away at the age of 86, leaving behind a legacy of innovation in blood purification for critical care. His work has greatly influenced the treatment of life-threatening conditions.
Read more →CTSOCytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
CytoSorbents Corporation will showcase new data on its blood purification technologies at the EACTS Annual Meeting in Copenhagen from October 8-11, 2025. The presentations will include findings from randomized trials and real-world studies demonstrating the effectiveness of CytoSorb and DrugSorb-ATR in cardiac surgery. The event is expected to draw over 5,000 attendees from the cardiothoracic community.
Read more →CTSOCytoSorbents Provides DrugSorb-ATR Regulatory Update
CytoSorbents Corporation announced a regulatory update on DrugSorb-ATR, revealing that the FDA upheld its previous denial of the De Novo application but found no safety issues. The FDA suggested a potential expedited path for market authorization. The company plans to align with the FDA for a new application while also addressing regulatory matters in Canada.
Read more →CTSOCytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day
CytoSorbents Corporation is hosting a global webinar titled "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" on September 10, 2025. The event will feature Dr. Phillip Chan and international experts discussing the use of CytoSorb therapy in treating sepsis and septic shock. This initiative coincides with Sepsis Awareness Month and aims to enhance understanding and treatment strategies for these critical conditions.
Read more →CTSOCytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CytoSorbents Corporation will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The company is recognized for its blood purification technologies used in critical care. Despite recent setbacks with FDA and Health Canada, CytoSorbents continues to seek regulatory approvals and engage with investors.
Read more →CTSO▼ -17.2%on this news
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authoriz
CytoSorbents Corporation updated its FDA regulatory status regarding the DrugSorb-ATR device. The FDA upheld the denial of the De Novo application but identified no safety issues with the device. Instead, it proposed a potential pathway for market authorization, which the company is exploring in ongoing discussions with the FDA. Additionally, CytoSorbents is evaluating options for appealing the decision at a higher level within the FDA and addressing a similar refusal from Health Canada for its device approval.
Read more →CTSOCytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update
CytoSorbents Corporation reported Q2 2025 financial results showing a revenue increase of 9%, reaching $9.6 million, and a net income of $1.9 million. The company highlighted strong sales growth in Germany and provided updates on its regulatory efforts for the DrugSorb-ATR device with the U.S. FDA. Despite facing some operational losses and a decrease in gross margin, management remains optimistic about future sales growth and advancements in treating sepsis. The firm will also host a global webinar focusing on sepsis treatment later in September.
Read more →CTSO▼ -7.6%on this news
CytoSorbents Leads a New Era in Sepsis Treatment CytoSorbents highlights the vital and evolving role of CytoSorb in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10 th
CytoSorbents Corporation is emphasizing the significant advancements of its CytoSorb therapy in combating sepsis and septic shock, particularly as it prepares for its World Sepsis Day Global Webinar on September 10, 2025. Recent studies have highlighted that early and intensive application of CytoSorb therapy notably improves patient outcomes in critical care settings. Dr. Phillip Chan, CEO, underscores the therapy's broad-spectrum blood purification capabilities, which address severe inflammation and organ failure while supplementing standard antibiotic treatments. The company continues to gather substantial clinical evidence demonstrating the therapy's unique benefits in saving lives amidst the ongoing challenge of sepsis treatment.
Read more →CTSOCytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation will report its second quarter 2025 financial results and recent business highlights on August 7, 2025. The company has faced regulatory challenges, including a denial from the FDA regarding its DrugSorb-ATR device and a refusal from Health Canada on its Medical Device License application. Despite these setbacks, CytoSorbents remains committed to addressing the identified deficiencies through appeal processes with both regulatory bodies. The company is also planning to hold a conference call to discuss these results and updates with investors.
Read more →CTSO▼ -22.5%on this news
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR PRINCETON, N.J.
CytoSorbents Corporation provided an update on its marketing applications for DrugSorb-ATR with the FDA and Health Canada. Despite receiving a De Novo Denial Letter from the FDA and a Notice of Refusal from Health Canada, the company remains optimistic about resolving the issues through the appeals processes. DrugSorb-ATR aims to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting. The company plans to submit a Request for Reconsideration to Health Canada and believes resolution can be achieved by the end of 2025.
Read more →CTSOCytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb -ATR PRINCETON, N.J.
CytoSorbents Corporation has filed a supervisory review appeal with the U.S. FDA regarding the De Novo Denial Letter for its DrugSorb-ATR device, aimed at reducing the severity of bleeding in patients on antiplatelet medication during CABG surgery. The company aims to address the FDA's identified deficiencies through this process, which is expected to take approximately 60 days for a decision. CytoSorbents is optimistic about resolving the issues effectively, emphasizing the urgency of DrugSorb-ATR for patients needing immediate surgical intervention.
Read more →CTSOCytoSorbents to Participate at the Jefferies Global Healthcare Conference
CytoSorbents Corporation (NASDAQ: CTSO) announced its participation in the Jefferies Global Healthcare Conference on June 4-5, 2025. The company will engage in one-on-one meetings with investors and present its innovative blood purification technologies. CytoSorbents is navigating regulatory challenges, having faced an FDA denial on its De Novo Request for DrugSorb-ATR, but plans to appeal the decision. Despite these hurdles, the company remains optimistic about potential resolutions in 2025.
Read more →CTSOCytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
CytoSorbents Corporation presented new data at EuroPCR 2025, demonstrating that their therapy significantly reduces severe bleeding in urgent CABG patients using ticagrelor. The analysis showcased a marked decrease in severe bleeding events, large transfusion needs, and re-operations due to bleeding. Importantly, no adverse events related to the device were reported, highlighting its safety and efficacy in clinical practice. The findings bolster support for routine use of CytoSorbents' device in surgical settings involving patients on blood thinners.
Read more →CTSO▼ -7.1%on this news
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update PRINCETON, N .J .
CytoSorbents Corporation (NASDAQ: CTSO) released its financial results for Q1 2025, highlighting a growth in distributor sales across the EU, which mitigated a temporary disruption in Germany linked to a reorganization of its sales strategy. The company remains optimistic about its initiatives to boost sales and patient outcomes through the use of its CytoSorb technology, which has shown significant improvements in clinical indicators. However, a denial from the FDA regarding the DrugSorb-ATR device's De Novo Request and delays in Health Canada's review process present challenges for the company's market expansion efforts.
Read more →CTSOCytoSorbents Provides Regulatory Update for DrugSorb-ATR PRINCETON, N.J.
CytoSorbents Corporation has provided a regulatory update regarding its DrugSorb-ATR device, aimed at reducing bleeding severity in CABG surgery patients. The FDA issued a denial letter to CytoSorbents, highlighting deficiencies that must be resolved before commercialization is possible. The company plans to continue discussions with the FDA to address these issues, and if necessary, will file a formal appeal. CytoSorbents remains committed to bringing this critical solution to market, emphasizing the significant medical need it addresses.
Read more →CTSOCytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation (NASDAQ: CTSO) will report its first quarter 2025 financial results and recent business highlights after the market closes on May 14, 2025. The management team will hold a live conference call and webcast to discuss these results and field questions from investors. CytoSorbents specializes in blood purification technologies for critical medical conditions and has seen success with its lead product, CytoSorb, which is approved in Europe and distributed globally. The company is also making strides in the U.S. with its investigational device, DrugSorb-ATR, aimed at reducing perioperative bleeding.
Read more →CTSOCytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces
CytoSorbents Corporation has appointed Melanie Grossman, CPA, as Vice President and Corporate Controller. With 25 years of experience in finance and accounting for publicly-traded companies, her role is expected to bolster the company's financial operations and compliance. The company aims to leverage her expertise to support growth initiatives and prepare for the potential launch of its DrugSorb-ATR device. This strategic appointment aligns with the company's ongoing development of blood purification technologies.
Read more →CTSOCytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America PRINCETON, N .J .
CytoSorbents Corporation has appointed Thomas Shannon as Vice President of Marketing for North America, effective April 14, 2025. Mr. Shannon will aid in the marketing strategy for DrugSorb-ATR, a device designed to minimize perioperative bleeding in cardiac surgery patients on blood thinners. His extensive experience in the marketing of cardiovascular technologies is expected to enhance the commercialization of this promising medical device. Regulatory approvals for DrugSorb-ATR are anticipated in 2025.
Read more →CTSOCytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants PRINCETON, NJ
CytoSorbents Corporation has announced an extension of the expiration date for its Series B Right Warrants from April 10, 2025, to June 10, 2025. This decision allows investors additional time to exercise their rights related to these warrants, which are linked to the company's Rights Offering from January 2025. The exercise price for these warrants is set between $2.00 and $4.00 based on the company's stock price. CytoSorbents continues to emphasize its role in critical care, particularly in blood purification technologies.
Read more →CTSOCytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights 2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR
CytoSorbents Corporation (NASDAQ: CTSO) reported its fourth quarter and full year 2024 financial results, highlighting a 15% growth in its core business. The company's treatments for life-threatening conditions have shown promising clinical data, notably improving survival rates for patients with septic shock. Despite this progress, CytoSorbents is facing challenges, particularly with flat sales in Germany and anticipated short-term disruptions due to a sales team reorganization. However, there are plans to expand the DrugSorb-ATR treatment in the U.S. and Canada, targeting a significant market potential.
Read more →CTSO▼ -9.8%on this news
CytoSorbents Reschedules Earnings Release to
CytoSorbents Corporation has announced the rescheduling of its fourth quarter and full year 2024 earnings call to March 31, 2025, to allow more time for the completion of its annual audit. The company reaffirmed its preliminary financial results and continues to expect regulatory decisions regarding its DrugSorb-ATR marketing applications in 2025. Recent fundraising efforts have raised a total of $7.85 million, enhancing the company's cash position.
Read more →CTSO▼ -9.8%on this news
CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit
CytoSorbents Corporation has postponed its earnings release for the fourth quarter and full year 2024 to March 31, 2025, to allow more time for the annual audit. Despite the delay, the company has reaffirmed its preliminary financial expectations, projecting a significant growth in product revenue. CytoSorbents also anticipates regulatory decisions on their DrugSorb-ATR marketing applications from the U.S. FDA and Health Canada within 2025. The upcoming earnings call will detail these developments and more.
Read more →CTSOCytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
CytoSorbents Corporation has postponed its earnings call originally set for March 6, 2025, to allow more time for its annual audit following the passing of its Corporate Controller, James E. Cason, Jr. The company plans to report its financial results on March 25, 2025, and continues to expect regulatory decisions for its DrugSorb-ATR product in 2025. The management expressed deep condolences for the loss of Mr. Cason.
Read more →CTSOCytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
CytoSorbents Corporation will announce its fourth quarter and full year 2024 financial results on March 6, 2025. The announcement will be accompanied by a live conference call and webcast. The company continues to lead in blood purification technologies, with its products used in critical care settings worldwide.
Read more →CTSOCytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
CytoSorbents Corporation announced it raised $1.6 million through the exercise of Series A Right Warrants, contributing to a total of $7.85 million raised. This strengthens the company's balance sheet, increasing liquidity to approximately $12.3 million. The company is also progressing with regulatory applications for its DrugSorb-ATR product, expecting decisions in 2025.
Read more →CTSO▲ +12%on this news
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
CytoSorbents Corporation has successfully closed an oversubscribed rights offering, raising $6.25 million. This funding satisfies a debt covenant, allowing $5 million in restricted cash to become available. The company aims to enhance its liquidity and drive innovation, particularly in the approval and launch of its DrugSorb-ATR product in 2025. Management is actively engaging with investors at the J.P. Morgan Healthcare Conference.
Read more →CTSO▲ +11%on this news
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
CytoSorbents Corporation has announced the opening of a new regional sales subsidiary in Dubai, aimed at enhancing its presence in the Middle East and Africa. This strategic move is expected to accelerate sales growth and improve support for existing partnerships. The subsidiary will serve as a hub for business development and customer engagement in a region experiencing rising demand for advanced medical technologies.
Read more →CTSOCytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
CytoSorbents Corporation reported preliminary unaudited financial results for Q4 and full-year 2024, highlighting a year-over-year product revenue growth of 22% to 25%. The gross margin is expected to improve to around 70%. The company is preparing to enter the North American market with its DrugSorb-ATR product, pending regulatory approvals. Full audited results are scheduled for release on March 6, 2025.
Read more →CTSO▼ -8.4%on this news
CytoSorbents Rights Offering Begins
CytoSorbents Corporation has initiated a Rights Offering for its stockholders, allowing them to acquire additional shares. This offering is part of the company's strategy to enhance its financial position and support its innovative blood purification technologies. The Rights Offering is backed by a detailed prospectus filed with the SEC, ensuring transparency for investors.
Read more →CTSO▼ -8.4%on this newsshared move
CytoSorbents Rights Offering Begins To Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on
CytoSorbents Corporation has announced the commencement of its Rights Offering, allowing eligible stockholders and certain Warrantholders to participate. Stockholders of record on December 16, 2024, will receive a non-transferable Subscription Right Warrant for every share they own. The offering is set to expire on January 10, 2025, and aims to provide funding for the company's operations and strategic initiatives. Detailed terms have been disclosed in a prospectus filed with the SEC, and the company encourages eligible participants to consult with their brokers or financial advisors.
Read more →CTSOCytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
CytoSorbents Corporation will hold in-person investor meetings in San Francisco during the J.P. Morgan Healthcare Conference from January 13-15, 2025. The meetings will be coordinated by ICR Healthcare, providing an opportunity for investors to engage with the company's management. CytoSorbents is known for its blood purification technologies used in critical care settings.
Read more →CTSOCytoSorbents Announces Rights Offering
CytoSorbents Corporation has announced a Rights Offering that allows current stockholders to purchase Units at a price of $1.00 per Unit. Each Unit consists of one share of common stock and two transferable Right Warrants for future purchases. The offering aims to generate proceeds between $3.0 million and $5.0 million, which will enhance the company's liquidity to support operations through upcoming regulatory decisions regarding their DrugSorb-ATR product. The Rights Offering has a deadline for exercise on January 10, 2025, with further details provided in a prospectus.
Read more →CTSOTHE TERMS AND CONDITIONS OF THE OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS DATED ______, 202__ (THE "PROSPECTUS") AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM
Cytosorbents Corporation has announced a subscription rights offering for holders of its common stock and eligible warrantholders. This offering allows participants to purchase units at a subscription price of $1.00 per unit, with each unit comprising one share of common stock and two related warrants. The offering will include an oversubscription privilege for existing rights holders and will expire on January 10, 2025, at 5:00 p.m. Eastern Time. For detailed terms, a prospectus is available on request.
Read more →CTSOCytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
CytoSorbents Corporation will participate in the Piper Sandler 36th Annual Healthcare Conference from December 3-5, 2024, in New York. CEO Dr. Phillip Chan and CFO Peter J. Mariani will hold one-on-one investor meetings on December 4. The company is known for its blood purification technologies used in critical care settings.
Read more →CTSO▲ +25.7%on this news
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents Corporation has announced a strategic partnership with Converge Biotech to enhance the treatment of sepsis and critical care conditions in India using its CytoSorb blood purification technology. This collaboration aims to leverage Converge's established network and sales force to increase the accessibility of CytoSorb in hospitals across the country, addressing significant health challenges such as septic shock and acute respiratory distress syndrome. Both companies anticipate that the partnership will lead to improved patient outcomes and a strengthened presence in India's rapidly growing critical care market.
Read more →CTSOCytoSorbents Reports Third Quarter 2024 Financial and Operational Results PRINCETON, N .J.
CytoSorbents Corporation announced their third-quarter financial results for 2024, showcasing 11% growth in product revenue to $8.6 million. The net loss was reduced to $2.3 million from $9.2 million in the same quarter last year. The company saw a decrease in product gross margins due to a planned production slowdown. They are actively pursuing regulatory approvals for their investigational device, DrugSorb-ATR, which could significantly impact the treatment of patients undergoing coronary artery bypass graft surgery, pending FDA and Health Canada reviews.
Read more →CTSO▼ -12.9%on this newsshared move
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
CytoSorbents Corporation has submitted a Medical Device License application for its DrugSorb-ATR device aimed at reducing CABG-related bleeding in patients treated with ticagrelor. This application follows the company's successful Medical Device Single Audit Program certification, which confirms compliance with quality management standards. The expected regulatory decisions from Health Canada and the U.S. FDA are anticipated in 2025, which could significantly impact the availability and effectiveness of the treatment in addressing an unmet medical need in cardiac surgery. The device aims to allow safer surgeries, potentially expediting treatment for heart attack patients.
Read more →CTSOCytoSorbents to Report Third Quarter 2024 Operating and Financial Results
CytoSorbents Corporation, a leader in blood purification for critical conditions, is set to report its third quarter 2024 operating and financial results after the market close on November 7, 2024. Management will host a conference call and presentation following the report. The company highlights its proprietary technologies used in life-threatening conditions, although specifics on current performance or challenges were not disclosed in the announcement.
Read more →CTSO▼ -10%on this news· ran to -21% by day 3
CytoSorbents Submits DrugSorb -ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update The De Novo medical de
CytoSorbents Corporation has submitted a De Novo marketing application for its DrugSorb-ATR device to the U.S. FDA, aimed at reducing perioperative bleeding in CABG patients on the blood thinner ticagrelor. The FDA previously granted Breakthrough Device Designation to the device, which underscores its potential to address a significant unmet medical need. The application is based on data from the STAR-T trial, which evaluated the device's effectiveness in removing ticagrelor during surgical procedures. The company also plans to submit a Health Canada Medical Device License application soon. Regulatory decisions are anticipated in 2025.
Read more →CTSOCytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CytoSorbents Corporation announced inducement equity awards granted to new CFO Peter J. Mariani, including options and restricted stock units that vest based on performance milestones. This move, compliant with Nasdaq Listing Rule 5635(c)(4), aims to align compensation with company goals. The awards will support the ongoing development and commercialization of CytoSorb, which plays a critical role in treating severe health conditions in the ICU and during cardiac surgeries.
Read more →CTSOCytoSorbents Reports Second Quarter 2024 Financial and Operational Results New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. Bloch On track for DrugSorb -ATR U.S. FDA De Novo and Health Canada marketing submis
CytoSorbents Corporation reported its financial results for the second quarter of 2024, highlighting progress toward regulatory approvals for its DrugSorb-ATR device. The company achieved a significant reduction in operating losses and strengthened its financial position through a term loan facility. New CEO Peter J. Mariani's appointment aims to bolster growth strategies, while product sales in the first half of 2024 showed a positive increase despite some challenges in direct sales. The company continues to focus on operational efficiency while preparing for the next stage of market expansion.
Read more →CTSOCytoSorbents Appoints Peter J. Mariani Chief Financial Officer CytoSorbents CFO Kathleen P. Bloch Retires PRINCETON, N.J.
CytoSorbents Corporation has announced the appointment of Peter J. Mariani as its new Chief Financial Officer, effective August 14, 2024. He succeeds Kathleen P. Bloch, who is retiring but will remain on as a consultant for a smooth transition. Mariani, with over 25 years of experience in the medical device industry, is expected to leverage his expertise to facilitate CytoSorbents' anticipated growth, particularly in seeking U.S. and Canadian approvals for their product, DrugSorb-ATR. The company continues to strengthen its position in life-saving blood purification technologies.
Read more →CTSO▲ +7.9%on this news
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO) will report its second quarter 2024 operating and financial results on August 13, 2024, after market close. A live conference call will be held on the same day to discuss these results. CytoSorbents is known for its advanced treatments for life-threatening conditions in critical care, including its approved product CytoSorb, which is effective in managing cytokine storms and postoperative complications. The company also has an investigational device, DrugSorb-ATR, aimed at improving patient outcomes during cardiothoracic surgery.
Read more →CTSOCytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J.
CytoSorbents Corporation announced that it has regained compliance with the Nasdaq minimum bid price requirement, as its stock has been priced at $1.00 or greater for ten consecutive trading sessions. This marks a positive development for the company, particularly as they prepare for anticipated regulatory submissions for their DrugSorb-ATR device to the U.S. FDA and Health Canada. CEO Dr. Phillip Chan stated that operational and financial changes have been made to strengthen the company’s market position moving forward. CytoSorbents continues to work on various avenues to enhance their product offerings in the treatment of critical conditions.
Read more →CTSOCytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
CytoSorbents Corporation announced the launch of its newly redesigned website, consolidating corporate and product information into a unified platform. The site aims to enhance accessibility for healthcare professionals, investors, and stakeholders, featuring intuitive navigation and a wide array of content. Key highlights include a resource library with over 1,000 publications and dedicated sections for news and investor relations. The redesign reflects the company's commitment to collaboration in improving patient outcomes through blood purification technology.
Read more →CTSOCytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
CytoSorbents Corporation (NASDAQ: CTSO) announced it will present at the inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress, taking place from July 18-22, 2024, in New York. CEO Dr. Phillip Chan will discuss the company's blood purification technologies and their role in treating critically ill patients, as well as participate in a panel on AI's impact on healthcare. The congress features over 3,000 medical professionals, creating a venue for innovative healthcare discussions.
Read more →CTSO▲ +17.4%on this news· ran to +44% by day 3
CytoSorbents Secures $20 Million Credit Facility
CytoSorbents Corporation has announced a new $20 million credit facility with Avenue Capital Group to enhance its financial position and support its CytoSorb product line. The funds will be utilized for working capital, refinancing existing debt, and preparing for potential FDA and Health Canada marketing applications for their investigational DrugSorb-ATR device. This device aims to address unmet medical needs in cardiac surgery, particularly for patients on blood thinners, presenting a potential openings in a large market if approved.
Read more →CTSO▲ +17.4%on this news· ran to +44% by day 3
CytoSorbents Secures $20 Million Credit Facility Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb as well as regulatory submissions and potential commercializat
CytoSorbents Corporation has announced a new $20 million credit facility from Avenue Capital Group aimed at enhancing its financial stability. The funds will be utilized for the global commercialization of its blood purification product CytoSorb and to support the regulatory submissions for DrugSorb-ATR in the U.S. and Canada. The credit facility includes an initial tranche of $15 million and potential further funding contingent on FDA approval. This move is pivotal as the company anticipates a significant market opportunity exceeding $0.5 billion for DrugSorb-ATR if successful in regulatory approvals.
Read more →CTSOCytoSorbents Announces Regulatory Approval of CytoSorb in Taiwan
CytoSorbents Corporation has received regulatory approval for its product CytoSorb in Taiwan, as announced on June 24, 2024. The approval, granted by the Taiwan Food and Drug Administration, allows for the use of CytoSorb in removing various harmful substances from the blood, such as cytokines and bilirubin. This is expected to enhance treatment options in Taiwanese intensive care units, where there is a significant need for effective therapies for critical illnesses. With CytoSorb already recognized in the European Union and utilized worldwide, the company aims to leverage its partnership with Hemoscien Corporation for distribution in Taiwan.
Read more →CTSOCytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
CytoSorbents Corporation has announced the launch and immediate availability of its PuriFi hemoperfusion machine in the European Union, following its approval under the EU Medical Device Regulation. The PuriFi pump features advanced innovations, such as an intuitive touchscreen interface and a quick 10-minute setup process. This product aims to address the growing demand for effective blood purification solutions in critical care settings. The launch is expected to enhance CytoSorbents' market presence and improve patient outcomes across various medical applications.
Read more →CTSO▲ +5%on this news
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
CytoSorbents Corporation (NASDAQ: CTSO) is set to host its 2024 Virtual Annual Stockholders Meeting on June 6, 2024. This meeting will provide updates and discussions pertinent to stockholders who are eligible to participate. The company continues to be a leader in blood purification treatments for critical illnesses in medical settings, with its product CytoSorb approved in various countries. Interested shareholders must have their unique control numbers to join the meeting.
Read more →CTSOCytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
CytoSorbents Corporation recently presented data from the STAR Registry at EuroPCR 2024, highlighting the use of CytoSorb in patients on ticagrelor undergoing CABG surgery. Professor Robert F. Storey shared outcomes from 102 patients, noting a promising reduction in severe bleeding rates compared to historical data. CytoSorb's efficacy supports its role as a potential practice-changing intervention. The company's advancements were recognized as a top finalist for best scientific abstract at the conference.
Read more →CTSOUnveiling the Impact of CytoSorb Therapy on Fluid Balance in Septic Shock Patients
The article discusses a study on CytoSorb therapy's impact on fluid balance in septic shock patients. Researchers found that using CytoSorb alongside continuous renal replacement therapy significantly improved fluid balance and reduced catecholamine requirements. This suggests that CytoSorb may help limit capillary leakage and enhance patient recovery. The findings indicate a potential shift in sepsis management strategies.
Read more →CTSO▼ -7.1%on this news
CytoSorbents Reports First Quarter 2024 Results
CytoSorbents Corporation reported strong financial results for the first quarter of 2024, showing a 14% increase in product sales year-over-year and a 22% sequential growth, totaling $9.0 million. The company is gearing up for potential FDA and Health Canada submissions for its DrugSorb-ATR device in Q3 2024, supported by positive results from the STAR-T trial. The quarterly gross margin improved to 76%, indicating enhanced operational efficiencies. A significant focus on launching the PuriFi hemoperfusion pump is also planned for 2024.
Read more →CTSO▼ -7.1%on this news
CytoSorbents Reports First Quarter 2024 Results Product Sales up a robust 14% over prior year, and a significant 22% sequentially Enhanced profitability with gross margins that surged an absolute 8% to reach 76%, reflect
CytoSorbents Corporation reported significant financial results for the first quarter of 2024, showcasing a 14% increase in product sales compared to the previous year and a remarkable 22% increase sequentially. The company's gross margins achieved 76%, indicating enhanced operational efficiency. Additionally, favorable feedback was received regarding the STAR-T trial's results presented at a medical association meeting, supporting the DrugSorb-ATR device's anticipated marketing applications. However, the company also faced a substantial decrease in grant income and a loss related to foreign currency transactions.
Read more →CTSOCytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
CytoSorbents Corporation is set to host a virtual Key Opinion Leader and Analyst-Investor Day on May 6, 2024, to discuss the STAR-T pivotal trial results. This event will focus on the challenges of severe perioperative bleeding and the usage of their investigational DrugSorb-ATR device. The session promises insights from leading experts in cardiac surgery, particularly regarding the removal of antithrombotic drugs in cardiac procedures. Additionally, real-world outcomes from Europe will be shared, highlighting the practical implications of this technology.
Read more →CTSOCytoSorbents to Report First Quarter 2024 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO) will announce its first quarter 2024 operating and financial results on May 9, 2024, after market close. The management will host a live conference call and webcast at 4:30 PM EDT to discuss the results, followed by a Q&A session. CytoSorbents is recognized for its innovations in blood purification for critical conditions, including its renowned product CytoSorb, which has been approved in the EU and utilized globally in various medical settings.
Read more →CTSO▼ -5.7%on this news· ran to -17% by day 3
Improving Heart Transplant Outcomes: The Role of CytoSorb
A recent randomized controlled trial investigated the use of CytoSorb® during orthotopic heart transplant surgeries. The study found that patients receiving CytoSorb® experienced improved hemodynamic stability, lower incidence of vasoplegic syndrome, and shorter vasopressor support duration compared to the control group. The intervention was deemed safe with no adverse events reported, suggesting a promising role for CytoSorb® in enhancing post-transplant outcomes.
Read more →CTSOCytoSorbents Reports Fourth Quarter and Full Year 2023 Results STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents inte
CytoSorbents Corporation reported its fourth quarter and full year results for 2023, showcasing a 10% increase in core sales and a gross margin improvement to 72%. While total revenue in Q4 2023 witnessed a decline of about 8% year-over-year, the company remains optimistic about the regulatory approval of DrugSorb-ATR, expected in the second half of 2024. The STAR-T trial, aimed at reducing bleeding complications in CABG surgeries, was selected for a breakout presentation at the upcoming AATS Annual Meeting, reflecting significant interest in its innovative approaches. Overall, CytoSorbents aims to clarify key factors for future success, including growth in non-COVID related business activities.
Read more →CTSOCytoSorbents to Report Fiscal 2023 Operating and Financial Results
CytoSorbents Corporation will announce its fiscal 2023 operating and financial results on March 14, 2024. The management team will provide updates on operational achievements during Q4 2023 and the full fiscal year, along with a live question-and-answer session. CytoSorbents is known for its innovative blood purification technology, particularly in critical care and cardiac surgery, and aims to further discuss its progress and future outlook during the call.
Read more →CTSOCytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
CytoSorbents Corporation (NASDAQ: CTSO) will present at the TD Cowen 44th Annual Health Care Conference on March 6, 2024, in Boston, MA. Dr. Phillip Chan, CEO, will lead the presentation, and management plans to meet with investors for one-on-one discussions during the event. The company is known for its blood purification technology aimed at treating severe conditions in critical care settings.
Read more →CTSOGroundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb Intraoperatively in Heart Transplant Patients CytoSorb Blood Purification Results in Statistically Significant Reductions in M
CytoSorbents Corporation announced positive results from a randomized controlled trial involving CytoSorb blood purification used during heart transplants. The trial, published in the ESC Heart Failure journal, demonstrated significant reductions in multiple organ failure and dysfunction among the treated group compared to standard care. The findings reinforce the clinical benefits of CytoSorb, suggesting it may be instrumental in improving outcomes for complex heart transplant patients and promoting its wider adoption in the field.
Read more →CTSO▲ +5.1%on this news
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Cytosorbents Corporation on behalf of stockholders due to concerns regarding potential violations of federal securities laws. This follows the announcement that Cytosorbents' pivotal trial for DrugSorb®-ATR did not achieve its primary effectiveness endpoint for reducing perioperative bleeding. The company's stock price dropped significantly, indicating investor concerns about the trial outcomes and possible legal ramifications.
Read more →CTSO▼ -33.4%on this news
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation PRINCETON, N.J.
CytoSorbents Corporation provided an update on the STAR-T trial, indicating that the independent Data and Safety Monitoring Board found no safety concerns regarding the DrugSorb-ATR device. While the overall trial did not meet its primary effectiveness endpoint, data suggest reduced bleeding risks in patients undergoing isolated coronary artery bypass graft surgery. The company is preparing for a detailed review of the complete study results, anticipating regulatory submissions to the U.S. FDA and Health Canada. The final trial results are expected to be presented at the American College of Cardiology 2024 conference.
Read more →CTSO▲ +21.5%on this news
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering Company insiders participated in the transaction with $435,000 of investment PRINCETON, N.J.
CytoSorbents Corporation has successfully closed a registered direct offering, raising $10.3 million through the sale of common stock and warrants. The financing saw participation from company insiders and institutional investors, highlighting strong support for the company's growth initiatives. The net proceeds from this offering are earmarked for clinical studies, regulatory efforts, and ongoing research and development. Additionally, the company is poised to release initial data from its pivotal STAR-T trial by the end of this month.
Read more →CTSO▼ -11.3%on this news
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains b
CytoSorbents Corporation reported a 20% increase in product sales, reaching $7.8 million in Q3 2023. The company is nearing completion of its pivotal STAR-T trial, which aims to demonstrate the effectiveness of DrugSorb-ATR in reducing bleeding in cardiothoracic surgery. Initial data analysis is expected before the end of the year, leading to potential U.S. FDA and Health Canada marketing applications in early 2024. Despite the positive sales growth, the outcomes of the trial remain blinded, creating uncertainty until the data can be analyzed.
Read more →CTSO▼ -7.8%on this news
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO) will announce its third-quarter 2023 operating and financial results on November 9, 2023. Following the announcement, the management team will host a live webcast and Q&A session for stakeholders. The company is recognized for its innovative blood purification technologies, particularly for critical illnesses, and is actively seeking FDA approval for its DrugSorb-ATR system to enhance surgical safety. This upcoming report could provide vital insights into the company's performance and future trajectory.
Read more →CTSOCytoSorbents to Present at the 8th Annual Dawson James Conference
CytoSorbents Corporation will showcase its blood purification innovations at the 8th Annual Dawson James Conference in Jupiter, FL on October 12, 2023. CEO Dr. Phillip Chan is scheduled to present, and the company will also hold one-on-one meetings with investors during the event. CytoSorbents is a leader in treating life-threatening conditions in ICU and cardiac surgery. Their lead product, CytoSorb, has significant global reach with over 212,000 units used worldwide.
Read more →CTSOCytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2 nd Analysis of the International STAR Registry PRINCETON, N.J.
CytoSorbents Corporation is set to present key findings at the EACTS 2023 conference in Vienna, focusing on the second analysis of the International STAR Registry. This analysis aims to illustrate the application of CytoSorb in reducing perioperative bleeding risks in patients on various antithrombotic medications during cardiac surgeries. The registry has reported low incidences of serious bleeding and no adverse events related to the device, which is encouraging for ongoing research in blood purification technologies. Additional presentations will discuss the use of hemoadsorption to improve surgical outcomes during complex procedures.
Read more →CTSOCytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer PRINCETON, N.J.
CytoSorbents Corporation has re-appointed Kathleen P. Bloch as its full-time Chief Financial Officer, effective retroactively to September 2, 2023. Bloch, who previously served as CFO for ten years before her retirement, resumes the role following the termination of former CFO Alexander D'Amico. The company aims to leverage upcoming opportunities, particularly seeking approvals for its DrugSorb-ATR technology in North America. Bloch expressed enthusiasm for the company's mission, emphasizing her commitment to guide CytoSorbents during this pivotal time.
Read more →CTSOCytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation In the first human retrospective study, CytoSorb and ex vivo lung perfusion prior to lung transplant increased in-hospital and
CytoSorbents Corporation (NASDAQ: CTSO) is leveraging its proprietary blood purification technology to enhance organ transplantation, particularly in lung transplants. The latest human retrospective study highlights successful outcomes, with increased in-hospital and one-year survival rates when combining CytoSorb with ex vivo organ perfusion. As donor organs remain scarce, this innovative approach aims to improve the viability of organs, reduce post-transplant complications, and ultimately save more lives in the critical area of organ transplantation.
Read more →CTSOCytoSorbents Announces Resignation of Chief Financial Officer Alexander D'Amico PRINCETON, N.J.
CytoSorbents Corporation announced the resignation of Chief Financial Officer Alexander D'Amico, effective August 28, 2023. His departure was part of a mutual termination agreement which includes no severance payments or vesting of equity. Kathleen Bloch will assume the role of Interim CFO under an existing consulting arrangement. This transition follows CytoSorbents' ongoing efforts in blood purification technology and its implications for the company's leadership structure.
Read more →CTSOCytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
CytoSorbents Corporation has received an expanded ANVISA registration for CytoSorb, allowing it to treat shock in Brazil. This therapy is critical for patients suffering from critically ill conditions and could significantly improve patient outcomes. The registration is expected to enhance the effectiveness of the Critical Care portfolio through its partnership with Fresenius Medical Care and Contatti Medical. With Brazil being Latin America's largest medical device market, this development marks a significant milestone for CytoSorbents in improving critical care treatment options.
Read more →CTSOCytoSorbents Reports Second Quarter 2023 Financial and Operational Results Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q
CytoSorbents Corporation reported an 11% increase in total revenue for Q2 2023, reaching $9.4 million compared to $8.5 million in the same quarter last year. The company highlighted a growth in product sales by 10%, indicating effective commercial strategies amidst a recovering market. CytoSorbents is nearing completion of its pivotal STAR-T randomized trial, with topline data expected before the end of the year. The firm is also preparing for regulatory submissions in the U.S. and Canada, anticipating a solid future for its DrugSorb-ATR product addressing critical cardiac needs.
Read more →CTSOCytoSorbents to Report Second Quarter 2023 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO) is set to report its second quarter 2023 operating and financial results on August 1, 2023, after market close. Management will host a live webcast and a conference call at 4:30 PM EDT on the same day for investors. The company is recognized for its work in critical care through blood purification, particularly with its lead product, CytoSorb, which has received regulatory approvals and expanded applications. As of Q1 2023, over 203,000 CytoSorb devices have been used globally.
Read more →CTSOCytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
CytoSorbents Corporation has appointed Alexander D'Amico as Chief Financial Officer, effective August 7, 2023. D'Amico brings over 20 years of financial expertise, notably from his previous role as CFO at Trulieve Cannabis Corporation, where he oversaw significant revenue growth. CEO Dr. Phillip Chan expressed enthusiasm for D'Amico's contributions to the firm's anticipated growth and strategy, particularly in expanding their CytoSorb business internationally. The transition follows the upcoming retirement of the former CFO, Kathy Bloch, who has significantly contributed to the company's management.
Read more →CTSOCytoSorbents Press Release CytoSorbents Appoints Alexander D'Amico as Chief Financial Officer PRINCETON, N.J.
CytoSorbents Corporation has appointed Alexander D'Amico as Chief Financial Officer, effective immediately. D'Amico brings over 20 years of finance experience, having previously served as CFO at Trulieve Cannabis Corporation, where he significantly increased revenue and managed complex acquisitions. The management team, including CEO Dr. Phillip Chan, believes D'Amico's expertise in finance and mergers will be vital for the company's expected growth, particularly in expanding its CytoSorb product internationally. D'Amico expressed excitement for the role, aiming to leverage his skills to aid CytoSorbents’ mission of saving lives and exploring new business opportunities.
Read more →CTSO▲ +11.5%on this news
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
CytoSorbents Corporation has partnered with Humedics GmbH to enhance liver disease treatment through a theranostic collaboration. The agreement focuses on combining CytoSorbents' blood purification technology with Humedics' LiMAx diagnostic tool to create a more effective approach to diagnosing and treating liver diseases. The companies will promote their technologies jointly, starting in several European countries, to improve market presence and accelerate the introduction of new diagnostic and therapeutic offerings. This collaboration underscores the urgent need for effective liver disease solutions, impacting millions worldwide.
Read more →CTSOCytoSorbents Completes Enrollment of the STAR-T Pivotal Trial PRINCETON, N.J.
CytoSorbents Corporation has announced the completion of enrollment for its pivotal Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) trial, which evaluates the effectiveness of DrugSorb-ATR in reducing perioperative bleeding in patients undergoing cardiothoracic surgery. This achievement reflects a high enrollment pace driven by the large unmet medical need as many eligible patients present at clinical sites. The results from the trial, aimed at supporting FDA and Health Canada marketing approval, will be presented at an international cardiovascular conference in early 2024. The company plans to expand its research on drug removal beyond ticagrelor in future trials.
Read more →CTSOCytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
CytoSorbents Corporation announced that the independent Data and Safety Monitoring Board (DSMB) has recommended proceeding with the pivotal STAR-T trial without modifications following a safety review. The trial, aimed at evaluating the DrugSorb-ATR system's efficacy in reducing surgical bleeding caused by the antithrombotic agent ticagrelor, will continue its enrollment as projected this summer. The positive recommendation reinforces confidence in the trial's design and execution, paving the way for future regulatory approvals in the U.S. and Canada.
Read more →CTSOCytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference
CytoSorbents Corporation is scheduled to host its Virtual Annual Stockholders Meeting on June 6, 2023, which will be accessible to eligible stockholders. CEO Dr. Phillip Chan is also set to present at the Jefferies Healthcare Conference on June 9, 2023, providing an opportunity for the company to engage with investors. The conference will feature a live webcast for broader participation. CytoSorbents specializes in blood purification technologies critical for treating life-threatening conditions.
Read more →CTSOCytoSorbents Reports First Quarter 2023 Results
CytoSorbents Corporation reported $9.4 million in total revenue for Q1 2023, reflecting a 9% increase from the prior year. The company achieved a new milestone of over 200,000 cumulative CytoSorb treatments globally and reached significant enrollment milestones in the STAR-T trial. Despite the positive growth in product sales and a strong cash position of $20.7 million, the company noted a decrease in product gross margins, attributed to start-up activities of a new manufacturing facility. Additionally, currency fluctuations had a detrimental impact on sales figures.
Read more →CTSOCytoSorbents Reports First Quarter 2023 Results Pivotal U.S. and Canada STAR-T Trial enrollment enters the last third of the study. Strong customer demand from Q4 2022 continued into Q1 2023, with current expectation of
CytoSorbents Corporation reported its financial and operational results for Q1 2023, highlighting strong customer demand and an encouraging enrollment rate in the STAR-T trial. The company is optimistic about achieving sales growth in 2023, fueled by a brisk demand for its products and effective cost management strategies, which helped reduce cash burn. However, the company did experience a slight decline in revenue compared to the same period last year, attributed to unfavorable exchange rates and the absence of sales related to COVID-19 treatments. Overall, the firm's outlook remains positive as it anticipates significant developments in the upcoming months.
Read more →CTSO▼ -8.9%on this news
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
CytoSorbents Corporation is set to report its first quarter 2023 operating and financial results on May 2, 2023. A live presentation and Q&A session will follow the announcement, allowing for further insights into the company's performance. CytoSorbents is known for its lead product, CytoSorb®, which is used in critical care settings to treat severe inflammatory conditions. The product has received both EU and FDA approvals for various applications, reflecting its importance in medical treatments.
Read more →CTSOCytoSorbents' Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled PRINCETON, N.J.
CytoSorbents Corporation announced that its pivotal STAR-T trial has successfully enrolled 80 patients, hitting the second of three key enrollment milestones. This rapid progress has triggered a safety review by the Data and Safety Monitoring Board. The company anticipates completing enrollment by summer, which would enable them to present top-line data later this year. The trial will assess the efficacy of DrugSorb-ATR in reducing the risk of bleeding during cardiothoracic surgery in patients using ticagrelor, with aims for FDA and Health Canada marketing approval.
Read more →CTSOCytoSorbents Announces Board Chairman Al W. Kraus To Retire PRINCETON, N.J.
CytoSorbents Corporation announced that its Chairman of the Board, Al W. Kraus, will retire at the end of his term in early June 2023. Kraus has served the company for 20 years, significantly impacting its growth and focus on blood purification technologies. His leadership helped pivot the company toward addressing critical health issues such as sepsis. While he will continue to be involved as a consultant, his retirement brings forth new leadership challenges.
Read more →CTSOCytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
CytoSorbents Corporation announced the presentation of new clinical data at the 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM) 2023 in Brussels. The data, showcased during a live symposium, focuses on the benefits of their therapy CytoSorb in reducing circulating cytokines during systemic inflammation and preventing endothelial damage. Various experts will present findings on CytoSorb’s impact on managing septic shock in pediatric patients, highlighting its growing importance in critical care medicine.
Read more →CTSOCytoSorbents Comments on Bank Exposure and Diversified Cash Position
CytoSorbents Corporation announced that it does not have any direct financial exposure to Silicon Valley Bank or Signature Bank. The company maintains diversified cash holdings across multiple financial institutions, primarily at JP Morgan Chase in the U.S. This financial strategy reduces risks associated with bank exposure. Additionally, CytoSorbents continues to focus on advancing its medical products, including its FDA-approved studies for its antithrombotic removal system.
Read more →CTSOCytoSorbents Reports Fourth Quarter and Full Year 2022 Results Pivotal U.S. and Canada STAR-T Trial enrollment passes halfway mark. Positive sales momentum from Q4 2022 continues in Q1 2023 to date, with expectation of s
CytoSorbents Corporation reported strong financial and operational results for Q4 2022, highlighting positive sales growth and significant progress in the STAR-T trial, which addresses perioperative bleeding risks. The company anticipates completion of enrollment in the pivotal trial by summer 2023, potentially enabling FDA and Health Canada marketing approvals. Despite challenges faced in 2022, CytoSorbents has seen an increase in core product sales and an expectation of continued growth into 2023. The firm also noted improvements in profit margins and efforts to reduce cash burn.
Read more →CTSO▲ +25.4%on this news· ran to +56% by day 3
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Cumulative CytoSorb treatments surpassed 195,000. Q4 2022 product sales rebounded from Q3 2022 low. Adjusted for co
CytoSorbents announced its preliminary financial results for Q4 and full year 2022, reporting total revenue of approximately $34.7M, primarily attributed to international sales of its flagship product, CytoSorb. The company highlighted significant achievements, including over 195,000 treatments administered and a rebound in product sales in Q4 compared to the previous quarter. CytoSorbents is pushing forward with the pivotal STAR-T trial for its second product, DrugSorb-ATR, aimed at addressing bleeding complications in patients undergoing cardiothoracic surgery. The company expects to complete patient enrollment for this trial by summer 2023 and aims to seek regulatory approvals thereafter.
Read more →CTSO▲ +17.6%on this news· ran to +50% by day 3
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement Non-dilutive debt capital at market favorable terms strengthens the balance sheet and provides additional working capit
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement Non-dilutive debt capital at market favorable terms strengthens the balance sheet and provides additional working capital to fund key clinical and commercial initiatives PRIN
Read more →CTSOCytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled PRINCETON, N.J.
CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled PRINCETON, N.J., November 14, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery
Read more →CTSOCytoSorbents Reports Third Quarter 2022 Financial and Operational Results CytoSorbents expects to achieve first milestone of the U.S. pivotal STAR-T Trial this month PRINCETON, N.J.
Reports Third Quarter 2022 Financial and Operational Results expects to achieve first milestone of the U.S. pivotal STAR-T Trial this month N.J., November 3, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensi
Read more →CTSO▼ -11.5%on this news
CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch PRINCETON, N.J.
CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch PRINCETON, N.J., October 7, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo
Read more →CTSO▲ +15.8%on this news
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey CytoSorb , DrugSorb -ATR, and ECOS-300CY now cleared for manufacturing from this site PRINCETON, N.J.
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey DrugSorb -ATR, and ECOS-300CY now cleared for manufacturing from this site PRINCETON, N.J., September 27, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment
Read more →CTSOCytoSorbents Reports Second Quarter 2022 Financial and Operational Results PRINCETON, N.J.
CytoSorbents Reports Second Quarter 2022 Financial and Operational Results PRINCETON, N.J., August 2, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purificati
Read more →CTSO▼ -5.7%on this news
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of Cyt
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb N.J., June 1, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a
Read more →CTSO▼ -8%on this news· ran to -22% by day 3
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million. Core non-COVID-19 product sales were an estimated $7.6 million, an
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million. Core non-COVID-19 product sales were an estimated $7.6 million, and on a constant currency basis were comparable to core p
Read more →CTSOFirst Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb -ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery
Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb -ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery JUNCTION, N.J., April 29, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threaten
Read more →CTSOCytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10 th EuroELSO Congress
CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress JUNCTION, N.J., April 28, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in
Read more →CTSOCytoSorbents To Expand Direct Sales of CytoSorb to the United Kingdom, the Sixth Largest Medical Device Market in the World
To Expand Direct Sales of CytoSorb to the United Kingdom, the Sixth Largest Medical Device Market in the World JUNCTION, N.J., April 14, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardi
Read more →CTSOCytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program JUNCTION, N.J., April 7, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac s
Read more →CTSOCytoSorbents Appoints Jiny Kim, MBA to its Board of Directors
CytoSorbents Appoints Jiny Kim, MBA to its Board MONMOUTH JUNCTION, N.J., April 5, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the ap
Read more →CTSO▲ +6.3%on this news
CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM)
CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM) MONMOUTH JUNCTION, N.J., March 17, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the int
Read more →CTSOCytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook 2021 total revenue was $43.2 million, including product sales of $40.1 million. Core non-COVID-19 product sales increased approxima
CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook was $43.2 million, including product sales of $40.1 million. Core non-COVID-19 product sales increased approximately 13% Y-Y to $33.8 anniversary of CytoSorb commercialization JUNCTION,
Read more →CTSO▲ +5.1%on this news
First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb to Restore Hemodynamic Stability in Patients with Refractory Septic Shock
Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb to Restore Hemodynamic Stability in Patients with Refractory Septic Shock JUNCTION, N.J., February 1, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-t
Read more →CTSO▲ +11.5%on this news
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal MONMOUTH JUNCTION, NJ - January 24, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the
Read more →CTSO▲ +5.3%on this news
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Preliminary Full Year 2021 Product Sales were approximately $40.1 million, including core non-COVID-19 sales growth
Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Full Year 2021 Product Sales were approximately $40.1 million, including core non-COVID-19 sales growth of approximately 13% from 2020. Cumulative CytoSorb treatments surpassed 162,000.
Read more →CTSO▼ -6.4%on this news
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) JUNCTION, N.J., December 20, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threate
Read more →CTSOCytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results Third Quarter 2021 total revenue was $9.8 million, including product sales of $8.9 million. Core non-COVID-19 product sales increased 3% Y-Y
CytoSorbents Reports Full Third Quarter 2021 total revenue was $9.8 million, including product sales of $8.9 million. Core non-COVID-19 product sales increased 3% Y-Y to approximately MONMOUTH JUNCTION, N.J., November 4, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a leade
Read more →CTSOCytoSorbents Comments on REMOVE Study Presentation
CytoSorbents Comments on REMOVE Study Presentation JUNCTION, N.J., October 20, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using CytoSorb 1 blood purification, makes additional c
Read more →CTSOFirst Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery MONMOUTH JUNCTION, N.J., October 14, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of li
Read more →CTSOCytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance Preliminary third quarter 2021 total revenue was $9.7 million, including product sales of $8.9 million. Preliminar
CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance Preliminary third quarter 2021 total revenue was $9.7 million, including product sales of $8.9 million. Preliminary core non-COVID-19 product sales increased 4% Y-Y to app
Read more →CTSO▼ -9.8%on this newsshared move
CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference
CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference MONMOUTH JUNCTION, N.J., October 7, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of
Read more →CTSOCytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb in Critically Ill Patients with COVID-19 Upcoming international webinar on
CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb in Critically Ill Patients with COVID-19 Upcoming international webinar on September 16, 2021 will summarize published clinical data from around the world on the use of CytoSorb in critically
Read more →CTSOCytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Su
Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery JUNCTION, N.J., September 10, 2021 - CytoSorbents Corporation (
Read more →CTSO▲ +5.6%on this news
CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb Adsorber and PerLife Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress MONMOUTH JUNCTION, N.
CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb Adsorber and PerLife Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress MONMOUTH JUNCTION, N.J., and BOLOGNA, ITALY, August 30, 2021 - CytoSorbents C
Read more →CTSOSecond U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery FDA
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery FDA Breakthrough Designation Granted to CytoSorbents' DrugS
Read more →CTSOCytoSorbents Reports Second Quarter 2021 Financial and Operational Results Total revenue increased 23% to $12.0 million. Core non-COVID-19 product sales increased 38% Y-Y, driving overall Q2 2021 product sales to $11.4 m
CytoSorbents Reports Second Quarter 2021 Financial Total revenue increased 23% to $12.0 million. Core non-COVID-19 product sales increased 38% Y-Y, driving overall Q2 2021 product sales to $11.4 million versus $9.5 million a year ago MONMOUTH JUNCTION, N.J., August 3, 2021 -
Read more →CTSOCytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery MONMOUTH JUNCTION, N.J., July 6, 2021 - CytoSorbents Corporation (NASDAQ: CTSO) announces the full approval of its Invest
Read more →CTSOCytoSorbents Reports First Quarter 2021 Financial and Operational Results Total revenue increased to $10.6M. Q1 2021 CytoSorb product sales grew 24% to $10.1M versus $8.2M a year ago
CytoSorbents Reports First Quarter 2021 Financial and Operational Results Total revenue increased to $10.6M. Q1 2021 CytoSorb product sales grew 24% to $10.1M versus $8.2M a year ago MONMOUTH JUNCTION, N.J., May 4, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a critical c
Read more →CTSOU.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery
U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery MONMOUTH JUNCTION, N.J., April 19, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader whose flagship E.U. approved CytoSorb blood purification
Read more →CTSOCytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey
Announces Lease of New Global Headquarters in Princeton, New Jersey JUNCTION, N.J., March 29, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critical
Read more →CTSOCytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery
Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery JUNCTION, N.J., March 16, 2021 - CytoSorbents Corporation (NASDAQ: CTSO) announces the filing of an Investigational Device Exemption (IDE) applicati
Read more →CTSOCytoSorbents Announces 2020 Financial and Operational Results 2020 Total Revenue was $41.0 million, with 2020 Product Sales of $39.5 million, up 73% over 2019. Achieved record Product Gross Margins of 82% for Q4 2020
Announces 2020 Financial and Operational Results Total Revenue was $41.0 million, with 2020 Product Sales of $39.5 million, up 73% over 2019. Achieved record Product Gross Margins JUNCTION, N.J., March 9, 2021 - CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunother
Read more →CTSOCytoSorbents 2021: Leadership and Growth in the "New Normal"
CytoSorbents 2021: Leadership and Growth MONMOUTH JUNCTION, NJ - February 18, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and card
Read more →CTSOCytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue Preliminary Full Year and Q4 2020 Product Sales were $39.5 million and $11.5 million, respectively, representing growth of 73% and 74%, respectiv
CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue Preliminary Full Year and Q4 2020 Product Sales were $39.5 million and $11.5 million, respectively, representing growth of 73% and 74%, respectively, over the corresponding prior periods. Cumulative Cy
Read more →CTSOCytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank Eliminates long-term debt with flexibility of a new term loan commitment to fund future expansion, if needed
CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank long-term debt with flexibility of a new term loan commitment to fund future expansion, if needed JUNCTION, NJ - December 10, 2020 - CytoSorbents Corporation (NASDAQ: CTSO
Read more →CTSOCytoSorbents Reports Record Third Quarter 2020 Financial Results CytoSorbents reports record Q3 2020 Total Revenue of $10.5 million, including a 79% increase in Product Sales to $10.2 million, with $34.5 million in trail
Reports Record Third Quarter 2020 Financial Results reports record Q3 2020 Total Revenue of $10.5 million, including a 79% increase in Product Sales to $10.2 million, with $34.5 million in trailing 12-month Product Sales N.J., November 4, 2020 - CytoSorbents Corporation (NASDA
Read more →CTSOCytoSorbents Reports Record Second Quarter 2020 Financial Results CytoSorbents posts record Q2 2020 Total Revenue of $9.8 million, including a 61% increase in Product Sales to $9.5 million, with $30 million in trailing 1
CytoSorbents Reports Record Second Quarter 2020 Financial Results CytoSorbents posts record Q2 2020 Total Revenue of $9.8 million, including a 61% increase in Product Sales to $9.5 million, with $30 million in trailing 12-month Product N.J., August 4, 2020 - CytoSorbents Corp
Read more →CTSOCytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock
CytoSorbents Corporation Announces Pricing of $50 Million Public Offering MONMOUTH JUNCTION, N.J., July 22, 2020 (PR Newswire) - CytoSorbents Corporation (Nasdaq: CTSO) (the "Company"), a critical care immunotherapy leader commercializing its CytoSorb blood purification techno
Read more →CTSOCytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update Achieved preliminary record total quarterly revenue of $9.8 million and product sales of $9.5 million, driven by demand for CytoSorb as a t
CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update Achieved preliminary record total quarterly revenue of $9.8 million and product sales of $9.5 million, driven by demand for CytoSorb as a treatment of cytokine storm in COVID-19 infection and oth
Read more →CTSOCytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise CytoSorb is now distributed in a total of 65 countries throu
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise CytoSorb is now distributed in a total of 65 countries throughout the world N.J., June 24, 2020 - CytoSorbents Corpo
Read more →CTSOCytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials
CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials MONMOUTH JUNCTION, N.J., June 9, 2020 - CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purific
Read more →CTSOCytoSorb is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery Expands CytoSorb E.U. label that now includes the reduction of two major
CytoSorb is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery Expands CytoSorb E.U. label that now includes the reduction of two major blood thinners, rivaroxaban (Xarelto ) and ticagrelor (Br
Read more →CTSOCytoSorbents Reports First Quarter 2020 Financial and Operational Results First Quarter 2020 Total Revenue grew 68% to $8.7M and Product Sales grew 78% to $8.2M over Q1 2019
CytoSorbents Reports First Quarter 2020 Financial and Operational Results 2020 Total Revenue grew 68% to $8.7M and Product Sales grew 78% to $8.2M over Q1 2019 N.J., May 5, 2020 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb
Read more →CTSOCytoSorbents Promotes Vincent J. Capponi to President
CytoSorbents Promotes Vincent J. Capponi MONMOUTH JUNCTION, N.J., May 4, 2020 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat cytokine storm and deadly inflammation in critical
Read more →CTSOCytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program Returning $1.4 Million Received from Paycheck Protection Program
CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program Returning $1.4 Million Received from Paycheck Protection Program MONMOUTH JUNCTION, N.J., April 29, 2020 /PRNewswire/ - CytoSorbents Corporation (NASDAQ:
Read more →CTSOCytoSorbents to Report Q1 2020 Operating and Financial Results
CytoSorbents to Report Q1 2020 Operating and Financial Results MONMOUTH JUNCTION, N.J., April 28, 2020 /PRNewswire/ - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly infla
Read more →CTSOCYTOSORBENTS APPOINTS DR. EFTHYMIOS N. DELIARGYRIS, M.D.
CYTOSORBENTS APPOINTS DR. EFTHYMIOS N. DELIARGYRIS, M.D., AS CHIEF MEDICAL OFFICER MONMOUTH JUNCTION, N.J., April 27, 2020 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadl
Read more →CTSODevelopment Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery
Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery MONMOUTH JUNCTION, N.J., April 20, 2020 -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care im
Read more →CTSONew Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on
New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO MONMOUTH JUNCTION, N.J., April 15, 2020 -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commer
Read more →CTSOCytoSorbents Announces 2019 Financial and Operational Results 2019 Total Revenue was $24.9 million, with 2019 Product Sales of $22.8M, and blended product gross margins of 80% for Q4 2019
Announces 2019 Financial and Operational Results was $24.9 million, with 2019 Product Sales of $22.8M, and blended product gross margins of 80% for Q4 2019 MONMOUTH JUNCTION, N.J., March 5, 2020 - CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader com
Read more →CTSOCytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter Growth accelerated in Q4 2019, with preliminary record total revenue of $7.4 million and record product sales of $6.6 million, driven
CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter Growth accelerated in Q4 2019, with preliminary record total revenue of $7.4 million and record product sales of $6.6 million, driven by a 30% increase in direct sales. Cumulative CytoSorb t
Read more →CTSOCytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study
CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study MONMOUTH JUNCTION, NJ - November 25, 2019 - CytoSorbents Corporation (NASDAQ: CTSO) is temporarily pausing enrollment of its REFRESH 2-AKI study at the recommendation
Read more →CTSODr. Eric Mortensen to Leave CytoSorbents At Year End
Dr. Eric Mortensen to Leave CytoSorbents N.J., November 6, 2019 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patient
Read more →CTSOCytoSorbents Reports Third Quarter 2019 Financial Results
Reports Third Quarter 2019 Financial Results JUNCTION, N.J., November 5, 2019 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery pat
Read more →CTSOFirst Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence
First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence JUNCTION, NJ - September 16, 2019 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification
Read more →CTSONASDAQ: CTSO HC Wainwright 21 st Global Investment Conference
NASDAQ: CTSO HC Wainwright 21 st Global Investment Conference September 10, 2019 HELPING REDUCE DEADLY UNCONTROLLED INFLAMMATION IN HOSPITALIZED PATIENTS WORLDWIDE Safe Harbor Statement 2 This presentation contains "forward - looking statements" pursuant to the safe harbor provi
Read more →CTSOCytoSorbents Reports Record Second Quarter 2019 Financial Results Q2 2019 Total Revenue was $6.2 million, with record quarterly product sales of $5.9 million and product gross margins of 76%
CytoSorbents Reports Record Second Quarter 2019 Financial Results Revenue was $6.2 million, with record quarterly product sales of $5.9 million and product gross margins of 76% N.J., August 6, 2019 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader
Read more →CTSOCyto Sorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy CytoSorbents Annual Meeting
Cyto Sorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy CytoSorbents Annual Meeting June 4, 2019 Safe Harbor Statement 2 This presentation contains "forward - looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation
Read more →CTSOCytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance
CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance N.J., May 7, 2019 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb blood purification technology to treat deadly inflammation i
Read more →CTSOCytoSorbents Achieves Record Revenue and Product Sales Growth in 2018 2018 Total Revenue was $22.5 million, with 2018 Product Sales surpassing $20M for the first time, representing 51% growth over 2017
Achieves Record Revenue and Product Sales Growth in 2018 was $22.5 million, with 2018 Product Sales surpassing $20M for the first time, representing 51% growth over 2017 MONMOUTH JUNCTION, N.J., March 7, 2019 - CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunothe
Read more →CTSOCytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial MONMOUTH JUNCTION, NJ - February 4, 2019 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purificatio
Read more →CTSOCytoSorbents Announces Expansion of CytoSorb Partnership with Fresenius Medical Care Agreement brings innovative CytoSorb therapy to Korea and Mexico and sets the stage for future growth
Announces Expansion of CytoSorb Partnership with Fresenius Medical Care Agreement brings innovative CytoSorb therapy to Korea and Mexico and sets the stage for future growth MONMOUTH JUNCTION, N.J., January 22, 2019 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care
Read more →CTSOCytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results CytoSorbents achieved another year of record growth with total revenue of more than $22.3 million, including product sales of approximately $
Issues Stockholder Letter with Preliminary 2018 Financial Results CytoSorbents achieved another year of record growth with total revenue of more than $22.3 million, including product sales of approximately $20.2 million, a 51% increase MONMOUTH JUNCTION, NJ - January 7, 2019
Read more →CTSOCytoSorbents Reports Third Quarter 2018 Financial Results Achieved record $19.1M in trailing 12-month product sales, up 63% from a year ago
CytoSorbents Reports Third Quarter 2018 Achieved record $19.1M in trailing 12-month product sales, up 63% from a year ago N.J., November 6, 2018 - CytoSorbents Corporation (Nasdaq: CTSO) a critical care immunotherapy leader commercializing its CytoSorb blood purification tec
Read more →CTSOCytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend Blood Transfusion Filter
Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend Blood Transfusion Filter MONMOUTH JUNCTION, N.J., August 21, 2018 - CytoSorbents Corporation (NASDAQ:CTSO) a critical care immunotherapy leader
Read more →CTSOCytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018 Quarterly CytoSorb Sales Reach $5.2 Million, With Trailing 12-month CytoSorb Sales of $17.4 Million
CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018 Quarterly CytoSorb Sales Reach $5.2 Million, With Trailing 12-month CytoSorb Sales of $17.4 Million N.J., August 2, 2018 - CytoSorbents Corporation CTSO) a critical care immunotherapy le
Read more →CTSOAferetica and CytoSorbents Debut the PerLife System for Organ Preservation and Rehabilitation at the 27 th International Congress of the Transplantation Society PerLife Is the First System Integrating a Sorbent Purificat
CytoSorbents Debut the PerLife System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society Is the First System Integrating a Sorbent Purification Technology to Perfuse, Cleanse, Recondition, and Preserve Harvested Solid O
Read more →CTSOCytoSorbents Added to the Russell 2000 and Russell 3000 Indexes
Added to the Russell 2000 and Russell 3000 Indexes MONMOUTH JUNCTION, N.J., June 26, 2018 -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardia
Read more →CTSOCytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility New facility quadruples production capacity and is expected to accelerate margin expansion and drive operating profitability
Officially Opens New U.S. CytoSorb Manufacturing Facility New facility quadruples production capacity and is expected to accelerate margin expansion and drive operating profitability MONMOUTH JUNCTION, N.J., June 12, 2018 -- CytoSorbents Corporation (NASDAQ: CTSO), a critical
Read more →CTSOCytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference
CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference MONMOUTH JUNCTION, N.J., June 4, 2018 -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb blood purification technology to treat deadly inflammation in c
Read more →CTSOCytoSorbents Reports Strong First Quarter 2018 Financial Results
Reports Strong First Quarter 2018 Financial Results N.J., May 8, 2018 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients aro
Read more →CTSOCytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank Extends the interest only period of the existing $10M debt by 18 months and adds the option for an additional $5M in debt
Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank the interest only period of the existing $10M debt by 18 months and adds the option for an additional $5M in debt N.J., April 4, 2018 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunot
Read more →CTSOCytoSorbents Corporation (NASDAQ: CTSO) Full Year 2017 and Q4 2017 Earnings and Operating Results Conference Call
CytoSorbents Corporation (NASDAQ: CTSO) Full Year 2017 and Q4 2017 Earnings and Operating Results Conference Call March 8, 2018 @ 4:45 pm Eastern This official company transcript has been edited for clarity and does not differ materially in content from the actual conference
Read more →CTSOCytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter CytoSorbents achieved record growth in 2017 with total revenue of more than $15 million, including CytoSorb s
Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter CytoSorbents achieved record growth in 2017 with total revenue of more than $15 million, including CytoSorb sales of approximately $13.2 million, with the goal achieving sustain
Read more →CTSOCytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application
Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application NJ, December 21, 2017 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb blood filter to treat deadly
Read more →CTSOCytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017 Company achieved record quarterly total sales of $3.8 million, and record quarterly and trailing twelve-month product sales of $3.4 million and
Continues Strong Trajectory of Growth in the Third Quarter 2017 record quarterly total sales of $3.8 million, and record quarterly and trailing twelve-month product sales of $3.4 million and $11.7 million, respectively JUNCTION, N.J., November 9, 2017 - CytoSorbents Corporati
Read more →CTSOCytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 Conference call today at 4:45 pm
CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 JUNCTION, N.J., August 7, 2017 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb blood filter to prevent or treat
Read more →CTSOAdditional $5 Million in Non-Dilutive Debt Financing from Bridge Bank
CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank N.J., July 5, 2017 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy specializing in blood purification, announced that on June 30, 2017 it received an
Read more →CTSODr. Eric R. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer Strengthens clinical trial capability with more than two decades of proven and successful clinical trial development
Dr. Eric R. Mortensen, M.D., Ph.D., Clinical Joins CytoSorbents as Chief Medical Officer Strengthens clinical trial capability with more than two decades of proven and successful clinical trial development expertise MONMOUTH JUNCTION, NJ - May 30, 2017 - CytoSorbents Corpora
Read more →CTSOCytoSorbents Reports First Quarter 2017 Financial Results Strong performance leads to increase in trailing 12-month CytoSorb sales of $9.2 million
Reports First Quarter 2017 Financial Results leads to increase in trailing 12-month CytoSorb sales of $9.2 million JUNCTION, N.J., May 8, 2017 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb blood filter to
Read more →CTSOCytoSorbents Announces Positive REFRESH I Trial Results Achieved the goals of this safety and feasibility study with demonstration of safe and significant reduction of toxic inflammatory mediators during complex open hea
Announces Positive REFRESH I Trial Results Achieved the goals of this safety and feasibility study with demonstration of safe and significant reduction of toxic inflammatory mediators during complex open heart MONMOUTH JUNCTION, N.J., May 5, 2017 - Positive results from the R
Read more →CTSOCytoSorbents 2017 - Propelling the Company to the "Next Level" Targeting significant annual sales growth, near-term operating profitability, a U.S. pivotal trial, and greater investor awareness and ownership
CytoSorbents 2017 - Propelling the Company to the "Next Level" Targeting significant annual sales growth, near-term operating profitability, a U.S. pivotal trial, and greater investor awareness and ownership MONMOUTH JUNCTION, NJ - April 19, 2017 - CytoSorbents Corporation (
Read more →CTSOCytoSorbents Announces Proposed Offering of Common Stock
CytoSorbents Announces Proposed Offering MONMOUTH JUNCTION, NJ, March 30, 2017 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb blood filter to treat deadly inflammation in critically-ill and cardiac surgery
Read more →CTSOCytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia
CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia MONMOUTH JUNCTION, NJ - March 28, 2017 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb
Read more →CTSOCytoSorbents Corporation (NASDAQ: CTSO) 2016 Earnings and Operating Results Conference Call
Corporation (NASDAQ: CTSO) 2016 Earnings and Operating Results Conference Call 3, 2017 @ 11am Eastern This official company transcript has been edited for clarity and does not differ materially in content from the actual conference call except where noted. Slide numbers hav
Read more →CTSOCytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results
CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results JUNCTION, NJ, January 10, 2017 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb blood filter to treat deadly inflammation in critically-ill and
Read more →CTSOCytoSorb Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago Exceeded $2M in CytoSorb Quarterly Sales for the First Time, and $2.4M in Total Revenue
Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago $2M in CytoSorb Quarterly Sales for the First Time, and $2.4M in Total Revenue JUNCTION, N.J., November 7, 2016 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flags
Read more →CTSOCytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial
Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial JUNCTION, N.J., Oct. 5, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a therapeutic device company commercializing its CytoSorb blood purification cartridge to control deadly inflammation in cr
Read more →CTSOCytoSorbents Achieves Fourth Consecutive Quarter of Record CytoSorb Sales Q2 2016 CytoSorb Revenues Up 140% over Q2 2015, REFRESH I Trial Nearing Completion
Achieves Fourth Consecutive Quarter of Record CytoSorb Sales Revenues Up 140% over Q2 2015, REFRESH I Trial Nearing Completion JUNCTION, N.J., August 9, 2016 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb b
Read more →CTSOCytoSorbents Closes $10 Million Debt Financing with Bridge Bank
Closes $10 Million Debt Financing with Bridge Bank MONMOUTH JUNCTION, N.J, July 1, 2016 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb blood purification cartridge to prevent or treat deadly inflammation an
Read more →CTSOCytoSorbents Continues Strong Growth in Q1 2016 Record quarterly sales up 127% from a year ago with continued consecutive quarterly growth
Continues Strong Growth in Q1 2016 sales up 127% from a year ago with continued consecutive quarterly growth JUNCTION, N.J., May 9, 2016 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb blood purification car
Read more →CTSOCytoSorbents Corporation (NASDAQ: CTSO) 2015 Earnings and Operating Results Conference Call
CytoSorbents Corporation (NASDAQ: CTSO) 2015 Earnings and Operating Results March 9, 2016 @ 4:45 pm Eastern This official company transcript has been edited for clarity and does not differ materially in content from the actual conference call except where noted. Slide numbers
Read more →CTSOCyto Sorbents Corporation NASDAQ: CTSO Working to Save Lives Through Blood Purification Biotech Showcase Presentation January 2016
Cyto Sorbents Corporation NASDAQ: CTSO Working to Save Lives Through Blood Purification Biotech Showcase Presentation January 2016 Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical Inc . a
Read more →CTSOCytoSorbents Corporation (Nasdaq:CTSO) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Dec. 22, 2015 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (Nasdaq:CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, will visi
Read more →CTSOCytoSorbents Accelerates Growth in Q3 2015
Accelerates Growth in Q3 2015 MONMOUTH JUNCTION, NJ - November 13, 2015 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb blood purification technology to reduce deadly uncontrolled inflammation in hospitalized pati
Read more →CTSOCytoSorbents Reports Steady Growth in Q2 2015
Reports Steady Growth in Q2 2015 MONMOUTH JUNCTION, NJ - August 13, 2015 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb(R) blood purification technology to reduce deadly uncontrolled inflammation in hospitalized pat
Read more →CTSOVeteran Healthcare Analyst Michael G. Bator Joins CytoSorbents Board of Directors
Veteran Healthcare Analyst Michael G. Bator Joins CytoSorbents Board of Directors MONMOUTH JUNCTION, N.J., July 15, 2015 -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to reduce deadly
Read more →CTSOCytoSorbents Reports 24% Year-over-Year Increase in CytoSorb Sales in First Quarter 2015
Reports 24% Year-over-Year Increase in CytoSorb Sales in First Quarter 2015 MONMOUTH JUNCTION, N.J., May 11, 2015 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy company commercializing its CytoSorb cytokine adsorber to treat critically-ill and cardia
Read more →CTSOCytoSorbents Corporation (NASDAQ CM: CTSO) 2014 Year End Earnings and Operating Results Conference Call
CytoSorbents Corporation (NASDAQ CM: 2014 Year End Earnings and Operating Results Conference Call March 31, 2015 @ 4:15 pm Eastern This official company transcript has been edited for clarity and does not differ materially from the actual conference call except where noted.
Read more →CTSOAnnounces Closing of Public Offering
Announces Closing of Public Offering JUNCTION, N.J. (January 14, 2015) CytoSorbents Corporation (NASDAQ: CTSO) today announced the closing of a $10.3 million underwritten public offering of 1,250,000 shares of common stock at a price of $8.25 per share to the public. The net p
Read more →CTSOCytoSorbents Receives NASDAQ Listing Approval Shares to Trade on The Nasdaq Capital Market beginning
Receives NASDAQ Listing Approval Shares to Trade on The Nasdaq Capital Market beginning December 23, 2014 MONMOUTH JUNCTION, N.J., December 18, 2014 - CytoSorbents Corporation (OTCQB: CTSOD), a critical care immunotherapy company commercializing its CytoSorb extracorporeal cy
Read more →CTSOCytoSorbents Announces Strategic Partnership with Fresenius Medical Care Monmouth Junction, N.J.
CytoSorbents Announces Strategic Partnership with Fresenius Medical Care Junction, N.J., December 15, 2014 CytoSorbents Corporation (OTCQB: CTSOD), a leader in critical care immunotherapy and blood purification, announced today that they have entered into a multi-country strat
Read more →CTSOCytoSorbents Reports Temporary Change of Stock Trading Symbol MONMOUTH JUNCTION, NJ--(
CytoSorbents Reports Temporary Change of Stock Trading Symbol MONMOUTH JUNCTION, NJ--(December 5, 2014) - CytoSorbents Corporation (OTCQB: CTSOD; OTCQB: CTSO), a critical care immunotherapy company specializing in blood purification to treat life-threatening illnesses, notifi
Read more →CTSOCytoSorbents Announces Appointment of New Board Director MONMOUTH JUNCTION, NJ--(
CytoSorbents Announces Appointment of New Board Director MONMOUTH JUNCTION, NJ--(November 14, 2014) - CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb cytokine adsorber to treat critically-ill patients in multiple coun
Read more →CTSOCytoSorbents Corporation (OTCBB: CTSO) Q3 2014 Earnings and Operating Results Conference Call
CytoSorbents Corporation (OTCBB: CTSO) Q3 2014 Earnings and Operating Results November 12, 2014 @ 4:15 pm Eastern This official company transcript has been edited for clarity and does not differ materially from the actual conference call. Slide numbers have been inserted to a
Read more →CTSOCyto Sorbents Corporation OTCQB : CTSO An Emerging Leader in Critical Care Immunotherapy Q3 2014 Review
Cyto Sorbents Corporation OTCQB : CTSO An Emerging Leader in Critical Care Immunotherapy Q3 2014 Review - November 12, 2014 Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents, Inc (now known as Cyt
Read more →CTSODear Shareholders and Friends, This is an exciting time for CytoSorbents Corporation ("CytoSorbents" or the "Company") and our shareholders. As previously disclosed, we are preparing to up-list our company from the OTCBB
Dear Shareholders and Friends, This is an exciting time for CytoSorbents Corporation ("CytoSorbents" or the "Company") and our shareholders. As previously disclosed, we are preparing to up-list our company from the OTCBB to a national securities exchange by the end of the year
Read more →CTSOPreliminary Q3 2014 Report: CytoSorbents Achieves Its First Quarter of Approximately $1M in CytoSorb Sales and Provides Up-listing Update
Preliminary Q3 2014 Report: CytoSorbents Achieves Its First Quarter of Approximately $1M in CytoSorb Sales and Provides Up-listing Update JUNCTION, N.J., October 14, 2014 - CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its Europe
Read more →CTSOCytoSorbents Corporation (OTCBB: CTSO) Q2 2014 Earnings and Operating Results Conference Call
CytoSorbents Corporation (OTCBB: CTSO) Q2 2014 Earnings and Operating Results August 12, 2014 @ 4:15 pm Eastern This official company transcript has been edited for clarity and does not differ materially from the actual conference call. Slide numbers have been inserted to all
Read more →CTSOCytoSorbents Corporation (OTCBB: CTSO) Q1 2014 Earnings and Operating Results Conference Call
Corporation (OTCBB: CTSO) Q1 2014 Earnings and Operating Results May 14, 2014 @ 4:15 pm Eastern This official company transcript has been edited for clarity and does not differ materially from the actual conference call. Slide numbers have been inserted to allow readers to f
Read more →CTSOCytoSorbents Corporation (OTCBB: CTSO) 2013 Earnings and Operating Results Conference Call
Corporation (OTCBB: CTSO) 2013 Earnings and Operating Results March 31, 2014 @ 4:15 pm Eastern This official company transcript has been edited for clarity and does not differ materially from the actual conference call. Slide numbers have been inserted to allow readers to fo
Read more →CTSOCytoSorbents Corporation Announces $10,200,000 Registered Direct Offering BY PR NEWSWIRE MARCH 7, 2014 09:31
CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering JUNCTION, N.J., March 7, 2014/PRNewswire/ - CytoSorbents Corporation (OTCBB: CTSO), a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional inves
Read more →CTSOCyto Sorbents Corporation OTCBB: CTSO An Emerging Leader in Critical Care Immunotherapy Biotech Showcase Presentation
Cyto Sorbents Corporation OTCBB: CTSO An Emerging Leader in Critical Care Immunotherapy Biotech Showcase Presentation January 15, 2014 Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiary CytoSorbents, Inc that are
Read more →CTSOCytoSorbents Corporation (OTCBB: CTSO) 2013 Third Quarter Earnings Conference Call Transcript
CytoSorbents Corporation (OTCBB: CTSO) 2013 Third Quarter Earnings Conference November 6, 2013 @ 4:15 pm Eastern Good day ladies and gentlemen. Thank you for standing by. Welcome to the CytoSorbents 2013 Third Quarter Earnings Conference Call. During today's presentation, all
Read more →CTSORodman & Renshaw Presentation OTCBB: CTSO Dr. Phillip Chan, MD, PhD - CEO September 2013 Working to Save Lives Through Blood Purification Cyto Sorbents Corporation Cyto Sorbents TM Safe Harbor Statement Statements in thi
Rodman & Renshaw Presentation OTCBB: CTSO Dr. Phillip Chan, MD, PhD - CEO September 2013 Working to Save Lives Through Blood Purification Cyto Sorbents Corporation Cyto Sorbents TM Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its o
Read more →CTSOCytoSorbents Corporation (OTCBB: CTSO) 2013 Shareholder Update Conference Call Transcript
Corporation (OTCBB: CTSO) Shareholder Update Conference Call Transcript 21, 2013 @ 4:15 pm Eastern Good day, ladies and gentlemen. Thank you for standing by. Welcome to the CytoSorbents 2013 Shareholder Update Conference Call. During today's presentation, all parties will be
Read more →CTSOCytoSorbents Provides Corporate Update and Reports Financial Results for the Period Ended
CytoSorbents Provides Corporate Update and Reports Financial Results for the Period Ended June 30, 2013 MONMOUTH JUNCTION, N.J., August 14, 2013 - CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company commercializing its European Union approved CytoSorb blood
Read more →CTSOCytoSorbents Appoints Dr. Rainer Kosanke as European Director of Scientific Affairs
MONMOUTH JUNCTION, N.J., July 8, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company commercializing its European Union approved CytoSorb blood filter to treat life-threatening illnesses in the intensive care unit, announced today that
Read more →CTSOCytoSorbents Announces Start of $1M US Army Phase II SBIR Contract and Closing of Additional Funding
Announces Start of $1M US Army Phase II SBIR Contract and Closing of Additional Funding JUNCTION, N.J., June 27, 2013 - CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb blood filter to treat life-threat
Read more →CTSOCytoSorbents Announces FDA Approved US Air Force Funded Human Trauma Pilot Study for Rhabdomyolysis
MONMOUTH JUNCTION, N.J., June 17, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit, announced today that the United States Food and Drug Administ
Read more →CTSOCytoSorbents Enters Into Exclusive Distribution Agreement for CytoSorb(R) With Hitit Medical Systems in Turkey
MONMOUTH JUNCTION, N.J., June 13, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses, announced today that is has entered into an exclusive distribution ag
Read more →CTSOCytoSorbents Reports 2013 First Quarter Financial Results
MONMOUTH JUNCTION, N.J., May 16, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO) is a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit. The Company's flagship product, CytoSorb , is the only speci
Read more →CTSOKATHLEEN P. BLOCH APPOINTED AS CHIEF FINANCIAL OFFICER OF CYTOSORBENTS MONMOUTH JUNCTION, NEW JERSEY (
KATHLEEN P. BLOCH APPOINTED AS CHIEF FINANCIAL OFFICER OF CYTOSORBENTS MONMOUTH JUNCTION, NEW JERSEY (May 13, 2013) - CytoSorbents Corporation (OTCBB: CTSO), a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses, today
Read more →CTSOCytoSorbents Enters Into Exclusive Distribution Agreement for CytoSorb(R) With L.IN.C. Medical Systems in the United Kingdom and Ireland
MONMOUTH JUNCTION, N.J., May 6, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses, announced today that is has entered into an exclusive distribution agre
Read more →CTSOCytoSorbents CEO Provides Exclusive Interview With medGadget
MONMOUTH JUNCTION, N.J., May 1, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO), a critical care-focused company using blood purification to treat life-threatening illnesses, announced that medGadget has published an online exclusive interview with CytoSorbents' Ch
Read more →CTSOCytoSorbents Appoints Christopher Cramer as Vice President of Business Development
MONMOUTH JUNCTION, N.J., April 15, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO), a critical care-focused company using blood purification to treat life-threatening illnesses in the intensive care unit, announced today that it has appointed Christopher Cramer, MS
Read more →CTSOCytoSorbents Awarded Additional Phase I Option on US Army SBIR Trauma Contract
MONMOUTH JUNCTION, N.J., April 11, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses, today announced the award of an additional Phase I Option SBIR (Smal
Read more →CTSOCytoSorbents Announces Trauma Advisory Board
MONMOUTH JUNCTION, N.J., April 8, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, today announced the establishment of its Trauma Advisory Board consisting of internation
Read more →CTSOCytoSorbents Provides Corporate Update and Reports 2012 Year End Financial Results
MONMOUTH JUNCTION, N.J., April 3, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit, provides a shareholder update and reports its financial resul
Read more →CTSOCytoSorbents Corporation , a critical care focused company using blood purification to treat life-threatening illnesses, today announced the appointment of Mr. Ronald Berger as Interim Chief Financial Officer. Mr. Berger
CytoSorbents Corporation , a critical care focused company using blood purification to treat life-threatening illnesses, today announced the appointment of Mr. Ronald Berger as Interim Chief Financial Officer. Mr. Berger replaces Mr. Thomas Bocchino, Chief Financial Officer, wh
Read more →CTSOCytoSorbents 2012 End of Year Shareholder Letter Monmouth Junction, NJ - (
CytoSorbents 2012 End of Year Shareholder Letter Monmouth Junction, NJ - (January 9, 2013) - CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, issued the following letter to shareholders. Dear
Read more →CTSOCytoSorbents Updates Corporate Progress and Third Quarter 2012 Financial Results Wednesday
Updates Corporate Progress and Third Quarter 2012 Financial Results Wednesday November 21, 2012 MONMOUTH JUNCTION, NJ-November 21, 2012 - CytoSorbents Corporation (OTCBB: CTSO), a critical care-focused company using blood purification to reduce inflammation as a means to pre
Read more →CTSOCyto Sorbents Rodman and Renshaw Presentation September 2012 OTCBB: CTSO Cyto Sorbents Corporation Working to Save Lives Through Blood Purification Cyto Sorbents 2 Safe Harbor Statement Statements in this presentation re
Cyto Sorbents Rodman and Renshaw Presentation September 2012 OTCBB: CTSO Cyto Sorbents Corporation Working to Save Lives Through Blood Purification Cyto Sorbents 2 Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidia
Read more →CTSOCyto Sorbents Investor Presentation June 2012 OTCBB: CTSO Cyto Sorbents Corporation Working to Save Lives Through Blood Purification Cyto Sorbents 2 Safe Harbor Statement Statements in this presentation regarding CytoSor
Cyto Sorbents Investor Presentation June 2012 OTCBB: CTSO Cyto Sorbents Corporation Working to Save Lives Through Blood Purification Cyto Sorbents 2 Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiary CytoSorbents
Read more →CTSOIn response to a number of shareholder questions, CytoSorbents Corporation posted the following FAQ section to its website on
In response to a number of shareholder questions, CytoSorbents Corporation posted the following FAQ section to its website on May 18, 2012. Q: If there is so much interest in CytoSorb, why are Q1 2012 sales low and why the decline from Q4 2011? Dr. Chan: First, let me reitera
Read more →CTSOCytoSorbents Strengthens Balance Sheet through Convertible Note Monmouth Junction, NJ - (
CytoSorbents Strengthens Balance Sheet through Convertible Monmouth Junction, NJ - (February 13, 2012) - CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it has raised $700,000 f
Read more →CTSOSHAREHOLDER LETTER CytoSorbents 2011 End of Year Shareholder Letter Monmouth Junction, NJ - (
CytoSorbents 2011 End of Year Shareholder Letter Monmouth Junction, NJ - (January 11, 2012) - CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, issued the following letter to shareholders. Dear S
Read more →CTSOCYTOSORBENTS ANNOUNCES PURCHASE AGREEMENT FOR UP TO $8.5 MILLION WITH LINCOLN PARK CAPITAL MONMOUTH JUNCTION, NEW JERSEY (
CYTOSORBENTS ANNOUNCES PURCHASE AGREEMENT FOR UP TO $8.5 MILLION WITH LINCOLN PARK CAPITAL MONMOUTH JUNCTION, NEW JERSEY (December 9, 2011) - CytoSorbents Corporation (OTC BB: CTSO), a critical care focused therapeutic device company using blood purification to treat life threat
Read more →CTSOUnassociated Document CytoSorbents Corporation Releases Shareholder Letter Monmouth Junction, NJ - (
CytoSorbents Corporation Releases Shareholder Letter Monmouth Junction, NJ - (June 6, 2011) - CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, issued the following letter to shareholders. Dear S
Read more →CTSOUnassociated Document CytoSorbents Corporation Achieves European Union Regulatory Approval for CytoSorb Monmouth Junction, NJ - (
CytoSorbents Corporation Achieves European Union Regulatory Approval for CytoSorb Monmouth Junction, NJ - (March 31, 2011) - CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, is pleased to announc
Read more →CTSOv204295_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
v204295_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
Read more →CTSOv189448_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
v189448_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
Read more →CTSOCYTOSORBENTS CORPORATION ENTERS INTO FUNDING AGREEMENT Monmouth Junction, New Jersey
CORPORATION ENTERS INTO Junction, New Jersey, May 10, 2010 - CytoSorbents Corporation (OTCBB: CTSO), formerly known as MedaSorb Technologies Corporation, a therapeutic device company, engaged in research, development, manufacture, and commercialization of blood purification t
Read more →CTSOUnassociated Document MedaSorb Technologies Announces Company Name Change to CytoSorbents Corporation Monmouth Junction, NJ - (
Technologies Announces Company Name Change to CytoSorbents Junction, NJ - (May 6, 2010) - MedaSorb Technologies Corporation, formerly trading under the symbol (OTCBB:MSBT), has formally changed its company name to CytoSorbents Corporation. Pursuant to the name change, effectiv
Read more →CTSOMedaSorb Technologies Corporation Raises $1.3M in Series B Warrant Exercise Monmouth Junction, NJ - (
Technologies Corporation Raises $1.3M in Series B Warrant Exercise Junction, NJ - (October 9, 2009) - MedaSorb Technologies Corporation (OTCBB:MSBT) and its wholly-owned subsidiary, CytoSorbents, Inc., announced that it has raised $1.3 million in the exercise of the warrant at
Read more →CTSOMedaSorb Technologies Corporation announces Management changes Monmouth Junction, NJ - (
Technologies Corporation announces Management changes Junction, NJ - (January 9, 2009) - MedaSorb Technologies Corporation (OTCBB:MSBT) and its wholly-owned subsidiary, CytoSorbents, Inc., announced that Dr. Phillip Chan has officially joined the Company as interim Chief Execu
Read more →CTSOUnassociated Document MEDASORB CORPORATION (fka MEDASORB TECHNOLOGIES, LLC) (a development stage company) FINANCIAL STATEMENTS DECEMBER 31, 2005 MEDASORB CORPORATION (a development stage company) CONTENTS
MEDASORB TECHNOLOGIES, LLC) development stage company) development stage company) Reports of Independent Registered Public Accounting Firms 1-2 Financial Statements: Balance Sheets 3 Statements of Operations 4 Statements of Changes in Stockholders' Equity (Deficiency) 5-9 Sta
Read more →Competitive Position
How CTSO ranks across every disease it competes inCompetitive Position is a premium feature
See how CTSO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial